Aggribloc 5mg Infusion

Product Description

1. Technical Specifications

2. Product Description

Aggribloc 5 mg Infusion contains Tirofiban Hydrochloride, a potent glycoprotein IIb/IIIa receptor antagonist. It prevents platelet aggregation and reduces the risk of clot formation. The infusion is mainly prescribed for acute coronary syndrome (ACS) such as unstable angina and non-ST elevation myocardial infarction (NSTEMI), and is often used during angioplasty (PCI) procedures. It is administered intravenously under hospital supervision along with aspirin and heparin.

3. Product Highlights

4. Therapeutic Uses

• Acute Coronary Syndrome (ACS):

  • Management of unstable angina and NSTEMI.

• Percutaneous Coronary Intervention (PCI):

  • Reduces clot risk during angioplasty/stent placement.

• Adjunctive Therapy:

  • Used with aspirin and heparin to improve treatment outcomes.

5. Side Effects

Common:

• Minor bleeding (injection site, gums, nosebleeds)

• Headache, nausea, dizziness

• Drop in blood pressure

Serious (less common):

• Major bleeding (GI tract, brain hemorrhage)

• Thrombocytopenia (low platelet count)

• Severe allergic reaction (rare)

6. Precautions

• Strictly for hospital use with continuous monitoring.

• Contraindications:

  • Active internal bleeding

  • Recent major surgery or trauma

  • History of hemorrhagic stroke

  • Severe uncontrolled hypertension

• Requires dose adjustment in patients with kidney impairment.

• Monitor platelet count, hemoglobin, hematocrit regularly.

• Avoid combination with other strong anticoagulants/antiplatelets unless directed.